← All Skye Bioscience, INC filings

Skye Bioscience, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SKYE
Skye Bioscience, INC
10-K: Skye Bioscience Reports 2024 Financial Results, Highlights Clinical Progress
Skye Bioscience details its financial performance for 2024 and provides updates on its clinical development programs, particularly focusing on nimacimab for obesity treatment.
NASDAQ
SKYE
Skye Bioscience, INC
10-K: Skye Bioscience Outlines Stock Structure and Clinical Development Plans in SEC Filing
Skye Bioscience details its capital structure, stock rights, and ongoing clinical programs for nimacimab and SBI-100 Ophthalmic Emulsion in its latest 10-K filing.